Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
SURG's Cash to Debt is ranked higher than
86% of the 389 Companies
in the Global Medical Devices industry.

( Industry Median: 3.52 vs. SURG: No Debt )
SURG' s 10-Year Cash to Debt Range
Min: 0.01   Max: No Debt
Current: No Debt

Equity to Asset 0.75
SURG's Equity to Asset is ranked higher than
79% of the 374 Companies
in the Global Medical Devices industry.

( Industry Median: 0.62 vs. SURG: 0.75 )
SURG' s 10-Year Equity to Asset Range
Min: 0.57   Max: 0.98
Current: 0.75

0.57
0.98
Interest Coverage 411.33
SURG's Interest Coverage is ranked higher than
70% of the 207 Companies
in the Global Medical Devices industry.

( Industry Median: 117.58 vs. SURG: 411.33 )
SURG' s 10-Year Interest Coverage Range
Min: 1.56   Max: 9999.99
Current: 411.33

1.56
9999.99
F-Score: 6
Z-Score: 4.35
M-Score: -2.42
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 5.90
SURG's Operating margin (%) is ranked higher than
73% of the 376 Companies
in the Global Medical Devices industry.

( Industry Median: 6.09 vs. SURG: 5.90 )
SURG' s 10-Year Operating margin (%) Range
Min: -8.11   Max: 19.44
Current: 5.9

-8.11
19.44
Net-margin (%) 4.08
SURG's Net-margin (%) is ranked higher than
73% of the 376 Companies
in the Global Medical Devices industry.

( Industry Median: 4.58 vs. SURG: 4.08 )
SURG' s 10-Year Net-margin (%) Range
Min: -7.41   Max: 13.89
Current: 4.08

-7.41
13.89
ROE (%) 4.25
SURG's ROE (%) is ranked higher than
70% of the 370 Companies
in the Global Medical Devices industry.

( Industry Median: 5.10 vs. SURG: 4.25 )
SURG' s 10-Year ROE (%) Range
Min: -4.88   Max: 12.96
Current: 4.25

-4.88
12.96
ROA (%) 3.09
SURG's ROA (%) is ranked higher than
73% of the 386 Companies
in the Global Medical Devices industry.

( Industry Median: 3.09 vs. SURG: 3.09 )
SURG' s 10-Year ROA (%) Range
Min: -4.55   Max: 10.2
Current: 3.09

-4.55
10.2
ROC (Joel Greenblatt) (%) 11.12
SURG's ROC (Joel Greenblatt) (%) is ranked higher than
71% of the 385 Companies
in the Global Medical Devices industry.

( Industry Median: 12.53 vs. SURG: 11.12 )
SURG' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -15   Max: 51.76
Current: 11.12

-15
51.76
Revenue Growth (%) 5.50
SURG's Revenue Growth (%) is ranked higher than
76% of the 306 Companies
in the Global Medical Devices industry.

( Industry Median: 4.60 vs. SURG: 5.50 )
SURG' s 10-Year Revenue Growth (%) Range
Min: -2.6   Max: 50.6
Current: 5.5

-2.6
50.6
EBITDA Growth (%) -21.80
SURG's EBITDA Growth (%) is ranked higher than
59% of the 280 Companies
in the Global Medical Devices industry.

( Industry Median: -2.90 vs. SURG: -21.80 )
SURG' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 115.4
Current: -21.8

0
115.4
EPS Growth (%) -24.20
SURG's EPS Growth (%) is ranked higher than
58% of the 268 Companies
in the Global Medical Devices industry.

( Industry Median: -2.00 vs. SURG: -24.20 )
SURG' s 10-Year EPS Growth (%) Range
Min: 0   Max: 122.4
Current: -24.2

0
122.4
» SURG's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

SURG Guru Trades in Q3 2013

Chuck Royce 539,574 sh (+121.96%)
Jim Simons 12,700 sh (-47.52%)
» More
Q4 2013

SURG Guru Trades in Q4 2013

Jim Simons 50,701 sh (+299.22%)
Chuck Royce 981,274 sh (+81.86%)
» More
Q1 2014

SURG Guru Trades in Q1 2014

Chuck Royce 1,491,274 sh (+51.97%)
Jim Simons 52,400 sh (+3.35%)
» More
Q2 2014

SURG Guru Trades in Q2 2014

Jim Simons 79,500 sh (+51.72%)
Chuck Royce 1,531,149 sh (+2.67%)
» More
» Details

Insider Trades

Latest Guru Trades with SURG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 23.80
SURG's P/E(ttm) is ranked higher than
83% of the 414 Companies
in the Global Medical Devices industry.

( Industry Median: 60.50 vs. SURG: 23.80 )
SURG' s 10-Year P/E(ttm) Range
Min: 5.03   Max: 196.15
Current: 23.8

5.03
196.15
P/B 1.20
SURG's P/B is ranked higher than
88% of the 414 Companies
in the Global Medical Devices industry.

( Industry Median: 3.39 vs. SURG: 1.20 )
SURG' s 10-Year P/B Range
Min: 0.49   Max: 9.59
Current: 1.2

0.49
9.59
P/S 1.19
SURG's P/S is ranked higher than
79% of the 414 Companies
in the Global Medical Devices industry.

( Industry Median: 3.15 vs. SURG: 1.19 )
SURG' s 10-Year P/S Range
Min: 0.34   Max: 7.18
Current: 1.19

0.34
7.18
EV-to-EBIT 14.21
SURG's EV-to-EBIT is ranked higher than
90% of the 414 Companies
in the Global Medical Devices industry.

( Industry Median: 57.20 vs. SURG: 14.21 )
SURG' s 10-Year EV-to-EBIT Range
Min: 5.4   Max: 153.4
Current: 14.21

5.4
153.4
Shiller P/E 17.40
SURG's Shiller P/E is ranked higher than
96% of the 414 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. SURG: 17.40 )
SURG' s 10-Year Shiller P/E Range
Min: 7.5   Max: 255
Current: 17.4

7.5
255
Current Ratio 6.46
SURG's Current Ratio is ranked higher than
91% of the 246 Companies
in the Global Medical Devices industry.

( Industry Median: 2.86 vs. SURG: 6.46 )
SURG' s 10-Year Current Ratio Range
Min: 1.73   Max: 30
Current: 6.46

1.73
30
Quick Ratio 4.34
SURG's Quick Ratio is ranked higher than
86% of the 246 Companies
in the Global Medical Devices industry.

( Industry Median: 2.09 vs. SURG: 4.34 )
SURG' s 10-Year Quick Ratio Range
Min: 0.68   Max: 14
Current: 4.34

0.68
14

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 6.60
SURG's Price/Net Current Asset Value is ranked higher than
87% of the 414 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. SURG: 6.60 )
SURG' s 10-Year Price/Net Current Asset Value Range
Min: 3.53   Max: 127.5
Current: 6.6

3.53
127.5
Price/Tangible Book 2.10
SURG's Price/Tangible Book is ranked higher than
84% of the 414 Companies
in the Global Medical Devices industry.

( Industry Median: 5.80 vs. SURG: 2.10 )
SURG' s 10-Year Price/Tangible Book Range
Min: 1.84   Max: 19.65
Current: 2.1

1.84
19.65
Price/DCF (Projected) 0.80
SURG's Price/DCF (Projected) is ranked higher than
98% of the 414 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. SURG: 0.80 )
SURG' s 10-Year Price/DCF (Projected) Range
Min: 0.73   Max: 15.63
Current: 0.8

0.73
15.63
Price/Median PS Value 0.60
SURG's Price/Median PS Value is ranked higher than
91% of the 414 Companies
in the Global Medical Devices industry.

( Industry Median: 1.10 vs. SURG: 0.60 )
SURG' s 10-Year Price/Median PS Value Range
Min: 0.21   Max: 4.69
Current: 0.6

0.21
4.69
Price/Graham Number 1.50
SURG's Price/Graham Number is ranked higher than
88% of the 414 Companies
in the Global Medical Devices industry.

( Industry Median: 7.20 vs. SURG: 1.50 )
SURG' s 10-Year Price/Graham Number Range
Min: 0.82   Max: 14.29
Current: 1.5

0.82
14.29
Earnings Yield (Greenblatt) 7.10
SURG's Earnings Yield (Greenblatt) is ranked higher than
81% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 4.60 vs. SURG: 7.10 )
SURG' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.7   Max: 18.4
Current: 7.1

0.7
18.4
Forward Rate of Return (Yacktman) 2.40
SURG's Forward Rate of Return (Yacktman) is ranked higher than
78% of the 307 Companies
in the Global Medical Devices industry.

( Industry Median: 1.36 vs. SURG: 2.40 )
SURG' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -6   Max: 1014.7
Current: 2.4

-6
1014.7

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Synergetics USA, Inc. is a Delaware corporation incorporated on June 2, 2005 in connection with the reverse merger of Synergetics, Inc. ('Synergetics') and Valley Forge Scientific Corp. ('Valley Forge'). Synergetics was founded in 1991. The Company is a supplier of precision surgical devices. The Company's main focus is on the disciplines of ophthalmology and neurosurgery. Its distribution channels include a combination of direct and independent distributor sales organizations and important strategic alliances with market leaders. The Company's product lines focus upon precision engineered, disposable and reusable devices, procedural kits and the delivery of various energy modalities for the performance of surgery, including: laser energy, ultrasonic energy, radio frequency energy for electrosurgery and lesion generation and visible light energy for illumination, and where applicable, simultaneous infusion (irrigation) of fluids into the operative field. It's ophthalmic and vitreoretinal surgical devices and equipment compete against manufacturers of similar products, including those sold by its major competitors, Alcon, Bausch & Lomb, Inc., Dutch Ophthalmic Research Center and Iridex. The Company is subject to macro-economic fluctuations in the United States, the countries of Europe and the economies of other countries throughout the world. Medical device companies are subject to rigorous regulation, including by the FDA and numerous other federal, state and foreign governmental authorities.
» More Articles for SURG

Headlines

Articles On GuruFocus.com
Synergetics USA: A Growth Story Amidst an Aging Population Aug 30 2012 
Synergetics Up 30% after Approval for Eye Surgery Device Jun 28 2012 
Synergetics USA Inc. (SURG) EVP & COO Kurt W Jr Gampp sells 43,000 Shares Mar 15 2011 
Weekly CFO Buys Highlight: CNLG, SIFID, FUL, SURG, TYL Jan 15 2011 
Synergetics USA Inc. (SURG) President and CEO David M Hable sells 17,000 Shares Jan 07 2011 
Weekly CFO Buys Highlight: COIN, INTC, SURG, IBCA, AUMN Oct 24 2010 
Synergetics USA, Inc. Announces 3 Month Extension of Current Agreements with Codman & Shurtleff, Inc Jan 07 2009 

More From Other Websites
SYNERGETICS USA INC Financials Jun 17 2014
Why Synergetics (SURG) Stock Is Lower Today Jun 10 2014
SYNERGETICS USA INC Files SEC form 8-K, Results of Operations and Financial Condition, Other Events,... Jun 09 2014
SYNERGETICS USA INC Files SEC form 10-Q, Quarterly Report Jun 09 2014
Synergetics Reports Third Quarter Fiscal Year 2014 Results Jun 09 2014
Synergetics Introduces the VersaVIT 2.0(TM) Jun 09 2014
Synergetics USA Announces Conference Call to Review Third Quarter of Fiscal Year 2014 Results May 30 2014
Synergetics USA Announces Cooperative Agreement to Develop Next Generation Intraoperative Devices May 12 2014
Synergetics USA Announces Launch of Next Generation Directional(TM) II Laser Probe May 05 2014
SYNERGETICS USA INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Mar 26 2014
Surg reports second fiscal quarter 2014 results Mar 26 2014
Synergetics (SURG) in Focus: Stock Tumbles 11.2% Mar 10 2014
Synergetics USA's CEO Discusses F2Q 2014 Results - Earnings Call Transcript Mar 06 2014
SYNERGETICS USA INC Files SEC form 8-K, Results of Operations and Financial Condition Mar 06 2014
Synergetics Reports Second Quarter Fiscal Year 2014 Results Mar 06 2014
Synergetics USA Announces Conference Call to Review Second Quarter of Fiscal Year 2014 Results Feb 20 2014
Time to Buy Synergetics (SURG) After Recent Moving Average Crossover? Jan 30 2014
SYNERGETICS USA INC Files SEC form 8-K, Change in Directors or Principal Officers Jan 14 2014
SYNERGETICS USA INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Jan 13 2014
SYNERGETICS USA INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of... Dec 13 2013

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide